Prescribing Isotretinoin for Transgender Patients: A Call to Action and Recommendations

J Drugs Dermatol. 2021 Jan 1;20(1):106-108. doi: 10.36849/JDD.5400.

Abstract

Case Scenerio: A 26-year-old patient presents to the dermatology clinic with severe nodulocystic scarring acne. The patient identifies as a transgender male and notes that he has been receiving hormone replacement therapy for the past 4 years with weekly intramuscular testosterone injections.

Publication types

  • Editorial

MeSH terms

  • Abnormalities, Drug-Induced / etiology
  • Abnormalities, Drug-Induced / prevention & control*
  • Acne Vulgaris / drug therapy
  • Acne Vulgaris / etiology
  • Adult
  • Dermatologic Agents / administration & dosage
  • Dermatologic Agents / adverse effects*
  • Dermatology / legislation & jurisprudence
  • Dermatology / standards
  • Drug Prescriptions / standards*
  • Female
  • Gender Identity
  • Humans
  • Isotretinoin / administration & dosage
  • Isotretinoin / adverse effects*
  • Male
  • Practice Guidelines as Topic / standards
  • Sex Reassignment Procedures / adverse effects
  • Sex Reassignment Procedures / methods
  • Testosterone / administration & dosage
  • Testosterone / adverse effects
  • Transgender Persons / legislation & jurisprudence*

Substances

  • Dermatologic Agents
  • Testosterone
  • Isotretinoin